Literature DB >> 32034922

Gut microbiota alterations affect glioma growth and innate immune cells involved in tumor immunosurveillance in mice.

Giuseppina D'Alessandro1,2, Fabrizio Antonangeli3, Francesco Marrocco1,4, Alessandra Porzia3, Clotilde Lauro1, Angela Santoni2,3, Cristina Limatola2,5.   

Abstract

Glioma is a CNS tumor with few therapeutic options. Recently, host microbiota has been involved in the immune modulation of different tumors, but no data are available on the possible effects of the gut-immune axis on brain tumors. Here, we investigated the effect of gut microbiota alteration in a syngeneic (GL261) mouse model of glioma, treating mice with two antibiotics (ABX) and evaluating the effects on tumor growth, microbe composition, natural killer (NK) cells and microglia phenotype. We report that ABX treatment (i) altered the intestinal microbiota at family level, (ii) reduced cytotoxic NK cell subsets, and (iii) altered the expression of inflammatory and homeostatic proteins in microglia. All these findings could contribute to the increased growth of intracranial glioma that was observed after ABX treatment. These results demonstrate that chronic ABX administration alters microbiota composition and contributes to modulate brain immune state paving the way to glioma growth.
© 2020 The Authors. European Journal of Immunology published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Antibiotics; Glioma; Gut microbiota; Innate immunity; NK cells

Year:  2020        PMID: 32034922     DOI: 10.1002/eji.201948354

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  28 in total

Review 1.  Clinical correlates for immune checkpoint therapy: significance for CNS malignancies.

Authors:  Nivedita M Ratnam; Stephen C Frederico; Javier A Gonzalez; Mark R Gilbert
Journal:  Neurooncol Adv       Date:  2020-11-27

2.  Integrated microbiome, metabolome, and proteome analysis identifies a novel interplay among commensal bacteria, metabolites and candidate targets in non-small cell lung cancer.

Authors:  Xiang Qian; Hong-Yan Zhang; Qing-Lin Li; Guan-Jun Ma; Zhuo Chen; Xu-Ming Ji; Chang-Yu Li; Ai-Qin Zhang
Journal:  Clin Transl Med       Date:  2022-06

3.  Crosstalk Between the Gut and Brain: Importance of the Fecal Microbiota in Patient With Brain Tumors.

Authors:  Yuping Li; Haixiao Jiang; Xiaolin Wang; Xiaoguang Liu; Yujia Huang; Zhiyao Wang; Qiang Ma; Lun Dong; Yajie Qi; Hengzhu Zhang; Guangyu Lu
Journal:  Front Cell Infect Microbiol       Date:  2022-06-17       Impact factor: 6.073

4.  Gut microbiome and neurosurgery: Implications for treatment.

Authors:  Jonathan Willman; Matthew Willman; Ramya Reddy; Anna Fusco; Sai Sriram; Yusuf Mehkri; Jude Charles; Joel Goeckeritz; Brandon Lucke-Wold
Journal:  Clin Transl Discov       Date:  2022-10-10

5.  Age at diagnosis and sex interact to modify primary malignant glioma incidence and survival.

Authors:  Judith Schwartzbaum; Randall Harris
Journal:  Neuro Oncol       Date:  2022-02-01       Impact factor: 12.300

6.  The role of gut microbiota in patients with benign and malignant brain tumors: a pilot study.

Authors:  Haixiao Jiang; Wei Zeng; Xiaoli Zhang; Yunlong Pei; Hengzhu Zhang; Yuping Li
Journal:  Bioengineered       Date:  2022-03       Impact factor: 6.832

7.  Human gut microbial communities dictate efficacy of anti-PD-1 therapy in a humanized microbiome mouse model of glioma.

Authors:  Kory J Dees; Hyunmin Koo; J Fraser Humphreys; Joseph A Hakim; David K Crossman; Michael R Crowley; L Burton Nabors; Etty N Benveniste; Casey D Morrow; Braden C McFarland
Journal:  Neurooncol Adv       Date:  2021-02-08

Review 8.  New Insights Into the Cancer-Microbiome-Immune Axis: Decrypting a Decade of Discoveries.

Authors:  Tejeshwar Jain; Prateek Sharma; Abhi C Are; Selwyn M Vickers; Vikas Dudeja
Journal:  Front Immunol       Date:  2021-02-23       Impact factor: 7.561

9.  Temozolomide-Induced Changes in Gut Microbial Composition in a Mouse Model of Brain Glioma.

Authors:  Xiao-Chong Li; Bang-Sheng Wu; Yi Jiang; Jie Li; Ze-Fen Wang; Chao Ma; Yi-Rong Li; Jie Yao; Xiao-Qing Jin; Zhi-Qiang Li
Journal:  Drug Des Devel Ther       Date:  2021-04-21       Impact factor: 4.162

Review 10.  Anti-PD-1 checkpoint blockade monotherapy in the orthotopic GL261 glioma model: the devil is in the detail.

Authors:  Zachariah P Tritz; Katayoun Ayasoufi; Aaron J Johnson
Journal:  Neurooncol Adv       Date:  2021-05-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.